Anemia in the Patient with Cancer

*Corresondence toAdrian Hunis, School of Medicine, Buenos Aires University, Argentina
Received: May 10, 2022; Accepted: June 06, 2022; Published: June 13, 2022
Citation: Hunis A, et al. (2022) Anemia in the Patient with Cancer. J Cancer Open Access 1:101.
Copyright: ©2022 Hunis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Anemia is a common complication in patients with cancer. It can be caused by either the tumor itself or the chemotherapeutic regimen used. The severity and prevalence of the condition varies based on a number of factors. Treatment is aimed at increasing the oxygen-carrying capacity of the blood, reducing fatigue, and improving the patient’s overall quality of life. Erythropoiesis-stimulating agents, iron supplementation, and red blood cell transfusions have all been recommended in different settings. While these have proven beneficial in some patients, the optimal therapeutic modality is yet to be established.Anemia is a major cause of morbidity in patients with cancer, linked with poor physical performance, prognosis, and therapeutic outcome. According to the World Health Organization (WHO), anemia is defined as a hemoglobin (Hb) level of <12 g/dL in nonpregnant women and <13 g/dL in men ≥15 years.